

# **Proposed Agenda & Faculty**



It is our great pleasure to announce the multinational congress MPN/MDS European Focus 2019 taking place at the Crowne Plaza Hotel, Belgrade, Serbia, scheduled for September 26-28 2019.

## We would like to invite you to be a part of this premier event!

Chaired by Srdan Verstovsek and Alessandro Vannucchi, the theme of the meeting, International Knowledge & Clinical Practice in 2019, reflects the collaboration to advance the research and treatment of patients with MPN & MDS globally.

MPN/MDS European Focus 2019 will host nearly 500 delegates and approximately 20 renowned faculty from the US and Europe. The meeting will provide participants with a unique opportunity for sharing knowledge, skills, and experiences. In addition, this activity will provide a platform for networking with many of the world's leading experts, focusing on reviewing and assessing best practices and state of the art treatments in MDS and MPN.

The meeting program will include presentations, round-table discussions, debates with audience participation, oral abstracts, poster sessions, and a number of informal social gatherings.



## Srdan Verstovsek, MD, PhD

Dr. Srdan Verstovsek is a Medical Oncologist and Dr. Srdan Verstovsek is a Medical Uncologist and Professor in the Department of Leukemia at The University of Texas MD Anderson Cancer Center, Houston, Texas. USA With research focused on understanding the biology of and developing new therapies for myeloproliferative neoplasms (MPNs) Member as a physician-scientist to The American Society for Clinical Investigation.



### Alessandro M. Vannucchi, MD

Dr. Alessandro Vannucchi is a Full Professor of Dr. Nessandro Vannucchi is a Full Professor of Hematology and head of the Center of Research and Innovation of Myeloproliferative Neoplasms AOU Careggi, University of Florence, Italy. Member of the board of GilMEMA. Investigator at (MPD-RC), funded by the NHI, USA

# **MPN/MDS European Focus 2019**



Register at mpn-mds2019.com

# Proposed Agenda & Faculty, September 26-28 2019

## **Thursday, September 26**

1. Registration

### 14:00

- Primer on eosinophilic neoplasms, Nick Cross
  Hematopathologist view: early MF vs ET vs masked PV, Hans-Michael Kvasnicka

- 4. Risk factors for PV revisited, Mirjana Gotic
- 5. Interferon for PV: are we there yet?, Heinz Gisllinger

- 6. Ruxolitinib for PV: what have we learned so far, Claire Harrison
- 7. Oral presentation of best abstracts

## Friday, September 27

8. Morning Symposium

9. Navigating multiple prognostic scoring systems for MF in everyday practice, Hernández-Boluda

10. Treating early-stage myelofibrosis, Francesca Palandri

11. Treatment of overt MF: practical and investigational combination strategies and second line therapies, Alessandro Vannucchi

12. Accelerated and blastic phase MPN, Srdan Verstovsek

13. Evolution of transplant approach for MF, Nikolaus Kroeger

14. Oral presentation of best abstracts

### 13:00

15. Lunch Symposium

16. An update on expectations and outcomes of cytoreductive therapies for ET patients - Gunnar Birgegard

17. Primer on systemic mastocytosis, Mohamad Jawhar

18. CMML: biology and therapy, Francesco Onida

19. JAK2 mutation positive splanchnic vein thrombosis +/- MPN: management in 2019, Tiziano Barbui

20. ICUS/CCUS/CHIP, Matteo Della-Porta

21. Oral presentation of best abstracts

## Saturday, September 28

22. Morning Symposium

23. Use of genetics in the management of MDS: my view, Magnus Tobiasson

24. Improving therapy for low risk MDS, Rajko Kusec

25. Improving therapy for high risk MDS, Lionel Ades

26. Reappraisal of transplant option in high-risk MDS, Uwe Platzbecker

27. Harnessing immunotherapy for MDS and CMML, Lisa Pleyer

28. Oral presentation of best abstracts

29. Lunch Symposium

International faculty:

expert insight & knowledge

mpn-mds2019@mdeducation.eu



